1. Academic Validation
  2. Structure-Guided Optimization of Selective Covalent Reversible Peptidomimetic Inhibitors Targeting TMPRSS6

Structure-Guided Optimization of Selective Covalent Reversible Peptidomimetic Inhibitors Targeting TMPRSS6

  • J Med Chem. 2025 Dec 25;68(24):26012-26029. doi: 10.1021/acs.jmedchem.5c01998.
Walid Guerrab 1 Matthieu Lepage 1 Antoine Désilets 1 Alexandre Joushomme 1 Michael Desgagné 1 Ulrike Froehlich 1 Richard Leduc 1 Pierre-Luc Boudreault 1
Affiliations

Affiliation

  • 1 Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada J1H 5N4.
Abstract

Developing selective Protease Inhibitors is a challenging task due to the high structural resemblance of their catalytic pockets. Here, we aimed to develop selective inhibitors targeting TMPRSS6, a protease involved in regulating iron homeostasis. By exploiting structural differences in the catalytic subpockets between TMPRSS6 and matriptase, we optimized ketobenzothiazole-based peptidomimetics using the P4-P3-P2-Arg-Kbt scaffold. We found that a combination of bulky residues at P4 and P3, along with polar Amino acids at P2, enhance selectivity while preserving high potency. Notably, WGU55 showed exceptional selectivity toward TMPRSS6 over matriptase and minimal off-target inhibition of coagulation serine proteases such as Factor Xa and Thrombin, representing, to our knowledge, the most selective TMPRSS6 inhibitor identified to date. Cell-based assays confirmed the inhibitor's high potency and selectivity. These findings validate a rational design strategy for the selective inhibition of TMPRSS6, paving the way for the development of targeted therapeutics based on peptidomimetics.

Figures
Products